Characterization of a conjugated polysuccinimide-carboplatin compound

Carboplatin, an advanced anticancer drug with excellent efficacy against ovarian cancer, was developed to alleviate the side effects that often occur with cisplatin and other platinum-based compounds. Our study reports the in vitro characteristics, viability, and activity of cells expressing the inducible nitric oxide synthase (iNOS) gene after carboplatin was conjugated with polysuccinimide (PSI) and administered in combination with other widely used anticancer drugs. PSI, which has promising properties as a drug delivery material, could provide a platform for prolonging carboplatin release, regulating its dosage, and improving its side effects. The iNOS gene has been shown to play an important role in both cancer cell survival and inhibition. Herein, we synthesized a PSI-carboplatin conjugate to create a modified anticancer agent and confirmed its successful conjugation. To ensure its solubility in water, we further modified the structure of the PSI-carboplatin conjugate with 2-aminoethanol groups. To validate its biological characteristics, the ovarian cancer cell line SKOV-3 and normal ovarian Chinese hamster ovary cells were treated with the PSI-carboplatin conjugate alone and in combination with paclitaxel and topotecan, both of which are used in conventional chemotherapy. Notably, PSI-carboplatin conjugation can be used to predict changes in the genes involved in cancer growth and inhibition. In conclusion, combination treatment with the newly synthesized polymer-carboplatin conjugate and paclitaxel displayed anticancer activity against ovarian cancer cells but was not toxic to normal ovarian cancer cells, resulting in the development of an effective candidate anticancer drug without severe side effects.

[1]  P. Kesharwani,et al.  Dendrimer as a promising nanocarrier for the delivery of doxorubicin as an anticancer therapeutics , 2021, Journal of biomaterials science. Polymer edition.

[2]  J. Nemunaitis,et al.  Ovarian Cancer Immunotherapy and Personalized Medicine , 2021, International journal of molecular sciences.

[3]  E. Pollet,et al.  Biological properties of novel polysuccinimide derivatives synthesized via quaternary ammonium grafting , 2020 .

[4]  Michal Kielbik,et al.  The Potential Role of iNOS in Ovarian Cancer Progression and Chemoresistance , 2019, International journal of molecular sciences.

[5]  M. Zrínyi,et al.  Kinetics of dopamine release from poly(aspartamide)-based prodrugs. , 2018, Acta biomaterialia.

[6]  R. Jove,et al.  Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer , 2018, Oncotarget.

[7]  J. Ledermann,et al.  Front-line therapy of advanced ovarian cancer: new approaches , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  V. Vinokurov,et al.  Paclitaxel Encapsulated in Halloysite Clay Nanotubes for Intestinal and Intracellular Delivery. , 2017, Journal of pharmaceutical sciences.

[9]  M. Potara,et al.  Carboplatin-Loaded, Raman-Encoded, Chitosan-Coated Silver Nanotriangles as Multimodal Traceable Nanotherapeutic Delivery Systems and pH Reporters inside Human Ovarian Cancer Cells. , 2017, ACS applied materials & interfaces.

[10]  H. Tajmir-Riahi,et al.  Review on the targeted conjugation of anticancer drugs doxorubicin and tamoxifen with synthetic polymers for drug delivery , 2017, Journal of biomolecular structure & dynamics.

[11]  Guojun Chen,et al.  Carboplatin-Complexed and cRGD-Conjugated Unimolecular Nanoparticles for Targeted Ovarian Cancer Therapy. , 2017, Macromolecular bioscience.

[12]  S. Jordan,et al.  Epidemiology of epithelial ovarian cancer. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[13]  R. Burger,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[15]  J. Coward,et al.  Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. , 2016, Critical reviews in oncology/hematology.

[16]  Robert Langer,et al.  Emerging Frontiers in Drug Delivery , 2016 .

[17]  Anjali Jain,et al.  Biodegradable polymers for targeted delivery of anti-cancer drugs , 2016, Expert opinion on drug delivery.

[18]  K. Lisowska,et al.  [Ovarian cancer--from biology to clinic]. , 2015, Postepy higieny i medycyny doswiadczalnej.

[19]  I. Joye,et al.  Biopolymer-Based Delivery Systems: Challenges and Opportunities. , 2015, Current topics in medicinal chemistry.

[20]  D. Brooks,et al.  Biodegradable polyglycerols with randomly distributed ketal groups as multi-functional drug delivery systems. , 2013, Biomaterials.

[21]  B. Kong,et al.  Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials , 2012, Journal of chemotherapy.

[22]  M. Zrínyi,et al.  Kinetics of volume change of poly(succinimide) gels during hydrolysis and swelling. , 2010, Physical chemistry chemical physics : PCCP.

[23]  C. Rao Nitric oxide signaling in colon cancer chemoprevention. , 2004, Mutation research.

[24]  Bernhard Brüne,et al.  Nitric oxide: NO apoptosis or turning it ON? , 2003, Cell Death and Differentiation.

[25]  Suyun Huang,et al.  Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. , 2003, Free radical biology & medicine.

[26]  R. Coleman Emerging role of topotecan in front-line treatment of carcinoma of the ovary. , 2002, The oncologist.

[27]  P. Hainaut,et al.  Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. , 2000, Biochemical and biophysical research communications.

[28]  T. Billiar,et al.  Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. , 1997, Biochemical and biophysical research communications.

[29]  N. Pavlidis,et al.  Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. , 1997, Seminars in oncology.

[30]  B. Brüne,et al.  Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. , 1996, The Biochemical journal.

[31]  C. Harris,et al.  Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P Rhodes,et al.  Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Couvreur,et al.  [Polymer nanoparticles for the delivery of anticancer drug]. , 2017, Medecine sciences : M/S.

[34]  H. Hamishehkar,et al.  Synthesis of a novel superdisintegrant by starch derivatization with polysuccinimide and its application for the development of Ondansetron fast dissolving tablet. , 2016, Drug development and industrial pharmacy.